Bibliography
- Carmona L, Villaverde V, Hernández-García C, et al. The prevalence of rheumatoid arthritis in the general population of pain. Rheumatology 2002;41:88-95
- Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatmentfor rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev 2013;12:835-8
- Furuya H, Kasama T, Isozaki T, et al. Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis. J Multidiscip Healthc 2013;6:25-30
- Smolen J, Landewe R, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75
- Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009;181:787-96
- National Institute for Health and Care Excellence Technology Appraisal 130: rheumatoid arthritis - adalimumab, etanercept and infliximab: guidance. Review 2010. Available from: http://www.nice.org.uk/nicemedia/pdf/ta130guidance.pdf
- Borrás-Blasco J, Gracia-Pérez A, Rosique-obles JD, et al. Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients. Expert Opin Biol Ther 2014;14:145-50
- Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn’s disease in a commercially-insured setting. Am J Ther 2006;13:502-6
- Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45
- Tornero Molina J, Sanmartí Sala R, Rodríguez Valverde V, et al. [Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis]. Reumatol Clin 2010;6:23-36
- Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75
- Borrás-Blasco J, Gracia-Pérez A, Rosique-Robles JD, et al. Adalimumab dose reduction in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients in sustained clinical remission. Ann Rheum Dis 2014;73:Suppl 2
- Raffeiner B, Botsios C, Sfriso P, et al. The effects of low dose etanercept on disease control and radiographic progression in moderate to severe rheumatoid arthritis. Arthritis Rheum 2010;62:S120
- Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial. Lancet 2013;381:918-29
- de la Torre I, Valor L, Nieto JC, et al. Anti-TNF treatments in rheumatoidarthritis: economic impact of dosage modification. Expert Rev Pharmacoecon Outcomes Res 2013;13:407-14
- Schabert VF, Watson C, Joseph GJ, et al. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm 2013;19:621-30
- Ramírez-Herráiz E, Escudero-Vilaplana V, Alañón-Plaza E, et al. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice. Clin Exp Rheumatol 2013;31:559-65